Pfizer Teams Up With Biocon In Bid to Dominate Global Biosimilar Insulin Market
This article was originally published in The Pink Sheet Daily
Pfizer tells analysts the deal will have an incremental not "instrumental" impact on its established products and emerging markets strategy.
You may also be interested in...
Mylan And India’s Biocon Team Up To Develop Insulin Biosimilars Of Sanofi, Lilly, Novo Nordisk Products
Less than a year after Pfizer broke out of a deal with Biocon, the company announced it is linking up with Mylan to make biosimilars of insulin products made by Sanofi, Lilly and Novo Nordisk.
With most eyes fixed on the imminent arrival of biosimilar antibodies – billed as the most valuable copy-cat biologics, given originators' high prices – it may be easy to overlook the potential of first-generation biosimilars such as insulin.
Lilly Not Ruling Out Pfizer Animal Health